Home › Funds › Lion Point Capital, LP › ARQT

Lion Point Capital, LP position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

Lion Point Capital, LP reported holding 5,250 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$138K, representing 0.66% of its reported portfolio and ranking #34 among its reported holdings. Lion Point Capital, LP has disclosed ARQT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)5.25K sh
Reported value held$137.66K
Portfolio Weight0.66%
First reportedQ3 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's ARQT position evolved

Lion Point Capital, LP first disclosed a stake in ARQT in Q3 2024 at 35,100 shares (US$326K). The position peaked in Q1 2025 at 46,300 shares, worth US$724K. Across 8 filings, Lion Point Capital, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 5,250 shares valued at US$138K. Notable position changes include a 32% increase in Q4 2024 (shares rose 12% over the following quarter), a 85% trim in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 35.10K $326.43K New
Q4 2024 46.30K $644.96K Add
Q1 2025 46.30K $724.13K Hold
Q2 2025 46.30K $649.13K Hold
Q3 2025 35.30K $665.40K Reduce
Q4 2025 5.25K $152.46K Reduce
Q1 2026 5.25K $123.69K Hold
Q2 2026 5.25K $137.66K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has Lion Point Capital, LP held ARQT?

Lion Point Capital, LP has disclosed ARQT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Lion Point Capital, LP's current position in ARQT?

As of Q2 2026, Lion Point Capital, LP holds 5.25K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $137.66K, representing 0.66% of its reported portfolio and ranking #34.

Has Lion Point Capital, LP been buying or selling ARQT?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in ARQT. The position peaked in Q1 2025 at 46.30K shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.